Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 9, 2015Cardiovascular & Haematological Disorders - Drug Targets

Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis

View Full Paper
Ask AI
Bookmark
Share

Key result

This review provides an overview of the efficacy and safety of novel oral anticoagulants compared to classic anticoagulants for the treatment and primary prevention of venous thromboembolism.

Why the study?

Do novel oral anticoagulants (NOACs) improve outcomes in patients with venous thromboembolism compared to classic anticoagulants?

Population

Patients with acute and chronic venous thromboembolism, including deep vein thrombosis and pulmonary…

Comparison

Novel oral anticoagulants including direct… vs Classic anticoagulants including heparin…

Design

Review

Authors

MAMuharrem AkinMedizinische Hochschule HannoverASAndreas SchäferInterventional CardiologyİAİbrahim AkınInterventional Cardiology

Discussion

Loading...

Member takes

Implication

Novel human observation in VTE; leaves open whether emerging targets improve outcomes beyond anticoagulation.

Structured PICO

Do novel oral anticoagulants (NOACs) improve outcomes in patients with venous thromboembolism compared to classic anticoagulants?

P
Population
Patients with acute and chronic venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), and patients requiring primary prevention of acute VTE
I
Intervention
Novel oral anticoagulants (NOACs) including direct thrombin inhibitors (dabigatran etexilate) and direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban)
C
Comparator
Classic anticoagulants including heparin, low-molecular-weight heparins (LMWHs), fondaparinux, and vitamin K antagonists

This review summarizes the role and evidence for novel oral anticoagulants (NOACs) in the treatment and primary prevention of venous thromboembolism.

Cite This Study

Akin et al. (2015) conducted a review in Venous Thromboembolism (VTE). Novel oral anticoagulants (NOACs) vs. Classic anticoagulants (heparin, LMWHs, fondaparinux, vitamin K antagonists) was evaluated. This review provides an overview of the efficacy and safety of novel oral anticoagulants compared to classic anticoagulants for the treatment and primary prevention of venous thromboembolism.

synapsesocial.com/papers/6a9fa29616360f1e481dddd3https://doi.org/10.2174/1871529x1502151209110620

Topics

Anticoagulation in AF
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement2009 · 696 citations
  2. 2Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty2008 · 1,439 citations
  3. 3Cardiovascular Risk Factors and Venous Thromboembolism Incidence2002 · 702 citations
  4. 4Incidence of Idiopathic Deep Venous Thrombosis and Secondary Thromboembolism among Ethnic Groups in California1998 · 346 citations